Stay updated on Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.

Latest updates to the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision history updated: added v3.4.2 and removed v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this internal version change does not alter user-facing content or functionality.SummaryDifference0.1%

- Check27 days agoChange DetectedNew: Show glossary toggle, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no substantive changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA top-level Locations section was added listing California, Massachusetts, New York, North Carolina, Texas, and Utah. The previous per-state location subsections (California Locations, Massachusetts Locations, New York Locations, North Carolina Locations, Texas Locations, Utah Locations) were removed.SummaryDifference0.7%

- Check91 days agoChange DetectedPublications now indicate that PubMed entries are automatically filled in from PubMed and may not relate to the study, and the revision label was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.